The U.S. Food and Drug Administration approved the uses of Vyvanse, marketed by Shire company, to treat binge-eating disorder. Under the marker of Vyvanse lisdexamfetamine dimesylate is hidden. The drug is the first FDA-approved medication to treat this condition.

The efficacy of Vyvanse in treating binge-eating disorder was shown in clinical studies that included 724 participants.

Participants taking Vyvanse experienced a decrease in the number of recurrent episodes of compulsive overeating.

The most common side effects reported by people taking Vyvanse included dry mouth, sleeplessness (insomnia) and anxiety. It should be noted that Vyvanse was approved in 2007 as a medication to treat attention deficit hyperactivity disorder. 

This syndrome and binge-eating have common features. In binge-eating disorder, patients have recurrent episodes of compulsive overeating. In fact, this is the greediness during the expression of stress. It is known that people with hyperactivity syndrome show a very expressed reaction against the stress.